Answers are grounded in this paper and cite their sources.
Background: Staging systems for cutaneous squamous cell carcinoma (CSCC) have improved remarkable in the last decade.Despite improvements in the clinician's ability to counsel patients on prognosis, significant gaps remain in the utilization of staging systems and stagebased treatment algorithms for CSCC.There are no current guidelines based on tumor stage; moreover, there is no distinction of the impact between different individual or combination risk factors.The small subset of tumors that have a substantial risk for recurrence and metastasis is becoming more defined, but how to use radiologic or invasive (e.g.sentinel lymph node biopsy (SLNB)) staging modalities or when to consider potential adjuvant therapies remains unclear.To address this practice gap, a multi-specialty expert panel will perform a multiple round Delphi study using various clinical scenarios in CSCC care.Our findings will help develop a systematic management algorithm for CSCC that follows staging systems as well as identify specific areas that need future clarification.Methods: 75 multi-specialty CSCC experts from dermatology, dermatologic surgery, radiation oncology, medical oncology, head & neck surgery, and surgical oncology were recruited and surveyed on their management approach in high-risk CSCC (see Table 1).A Delphi consensus process utilized a series of 3 iterative surveys sent to the expert panelists.Each survey round included clinical questions regarding a healthy, immunocompetent 65-year-old white male with a surgically resectable tumor located in the head and neck region.Tumor stages were defined based on the 8th American Joint Committee on Cancer criteria for CSCC. Demographics of PanelistsResults: 70 panelists participated in the first round of the Delphi survey.66 of those panelists completed the second and third rounds of the survey, with an overall completion rate of 94.3%.The panelists, including the steering committee, were 15 dermatologic surgeons, 15 medical dermatologists, 18 head & neck surgeons, 12 radiation oncologists, and 10 medical oncologists.The survey results are listed in Table 2.
No takes yet. Share an insight, caveat, or question.
Crüts et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: